Clinical trials: Stereotactic Body Radiation Therapy
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response.
- Trial name
- NCT06327178
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Prostate Cancer, Stereotactic Body Radiation Therapy
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor…
- Trial name
- START-MET (NCT05209243)
- Testing
- SBRT, STANDARD OF CARE
- Where
- 2 sites in Spain
- Volunteers
- 266 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Hypertension
Renal Denervation Using Stereotactic Radiotherapy System for the Treatment of Refractory Hypertension
This study is conducted to investigate the short-term safety and preliminary efficacy of stereotactic radiotherapy for renal denervation to treat refractory hypertension.
- Trial name
- NCT04198155
- Testing
- stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma…
- Trial name
- NCT04883671
- Testing
- Standard of Care, SBRT
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Pancreatic Adenocarcinoma
Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers
Pancreatic cancer is on the rise, and is set to become the 2nd leading cause of cancer deaths by 2030. Its prognosis is very poor, with a 5-year survival rate of just 5.5%.
- Trial name
- RAIPANC (NCT07097064)
- Testing
- standard radiotherapy with chemotherapy, MRI-guided adaptive stereotactic radiotherapy (SMART)
- Where
- 17 sites in France
- Volunteers
- 160 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Brain Metastasis, Oligoprogression
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Brain metastases (BM) are a common systemic cancer manifestation which incidence increases. Therapeutic options include whole-brain radiotherapy (WBRT), surgery, and stereotactic radiosurgery (SRS).
- Trial name
- OligoBM-01 (NCT05102747)
- Testing
- Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery)
- Where
- 15 sites in France
- Volunteers
- 504 people
- Sponsor
- Centre Francois Baclesse
Prostate Cancer
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
For this study, unfavorable intermediate risk prostate cancer patients will select whether they are to be treated with the standard of care (SOC) 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic…
- Trial name
- NCT06397703
- Testing
- Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- NYU Langone Health
Hepatocellular Carcinoma
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.
- Trial name
- NCT01918683
- Testing
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Primary Tumor, Metastatic Cancer
Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis
The purpose of this study is to determine how effective SBRT is compared to traditional radiation in treating the cancer that has spread to your spine and is causing pain.
- Trial name
- NCT01525745
- Testing
- Radiosurgery/SBRT, External Beam Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Melanoma, OligoProgressive Metastatic Disease
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients…
- Trial name
- CURB-Melanoma (NCT07112170)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
PDAC - Pancreatic Ductal Adenocarcinoma
A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
This Phase III randomized trial, evaluates whether adding targeted radiation (SBRT) and an immunotherapy drug (Serplulimab) to standard chemotherapy (GnP) can extend the lives of patients with advanced pancreatic cancer.
- Trial name
- NCT07336953
- Testing
- GnP, SBRT, Serplulimab
- Volunteers
- 198 people
- Sponsor
- West China Hospital
Arteriovenous Malformations
Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning
Evaluate whether a treatment plan based on CT angiography can accurately and precisely identify the target nidus as compared to standard cerebral arteriography fused to MRI.
- Trial name
- NCT03559556
- Testing
- CT angiography
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and…
- Conditions
- Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT03902951
- Testing
- Abiraterone Acetate, Apalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Cancer
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced…
- Trial name
- NCT01146054
- Testing
- CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Stanford University
Head and Neck Cancer
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- CKNO-RERT (NCT00738868)
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Oscar Lambret
Oligometastases
Stereotactic Body Radiation With Nelfinavir for Oligometastases
Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered.
- Trial name
- NCT01728779
- Testing
- Nelfinavir, Stereotactic Body Radiation (SBRT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreas Cancer, Locally Advanced
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced…
- Conditions
- Pancreas Cancer, Locally Advanced, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT05679674
- Testing
- Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Baptist Health South Florida
Pancreatic Tumor
Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer
The purpose of this study is to see if SBRT will be a better way to treat pancreas cancer and to find out what effects, good and/or bad, this treatment will have on participants and their cancer.
- Trial name
- NCT01434550
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Tissue, Blood, Research Imaging (TBRI)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.